IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models.

Marjolein C Stip,Mitchell Evers,Maaike Nederend,Chilam Chan,Karli R Reiding, Mirjam J Damen,Albert J R Heck, Sofia Koustoulidou,Ruud Ramakers,Gerard C Krijger,Remmert de Roos, Edouard Souteyrand,Annelisa M Cornel,Miranda P Dierselhuis,Marco Jansen, Mark de Boer,Thomas Valerius,Geert van Tetering,Jeanette H W Leusen,Friederike Meyer-Wentrup

Journal for immunotherapy of cancer（2023）

引用 3|浏览17

暂无评分

摘要

IgA3.0 ch14.18 is a promising new therapy for neuroblastoma, showing (1) increased half-life compared to natural IgA antibodies, (2) increased protein stability enabling effortless production and purification, (3) potent CD89-mediated tumor killing in vitro by healthy subjects and patients with neuroblastoma and (4) antitumor efficacy in long-term mouse neuroblastoma models.

查看译文

关键词

IgA, Neuroblastoma, Antibody Immunotherapy, Tumor Immunology, Neutrophils, Antibody Glycosylation, GD-2

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要